ArticleLife (Basel, Switzerland)2026
Biochemical and Clinical Characterization of a Patient with Partial Biotinidase Deficiency Carrying the Rare BTD c.690C>G (p.Phe230Leu) Variant: A Case Report.
Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biotinidase deficiency (BD) is an autosomal recessive inherited disorder in which the enzyme biotinidase (BTD) is totally or partially defective and the vitamin biotin is not recycled. More than 200 pathogenic variants in the BTD gene have been identified, causing complete or partial loss of enzyme activity and leading to profound or partial BD. Although the genotype-phenotype correlation is not fully defined, some genotypes are associated with profound forms and others with partial forms of BD. The patients with partial BD are mostly asymptomatic but symptoms may appear during stressful conditions such as infections. The patients with profound BD may present neurological problems, hearing loss, visual abnormalities, and organic aciduria, if not treated with biotin supplementation. BD is included in most newborn screening programs (NBS). Screening test relies on measurement of BTD enzyme activity in dried blood spot (DBS), followed by a plasma BTD assay and BTD molecular analysis as confirmatory test. We describe a male newborn with partial BD identified through the newborn screening program. Low BTD activity on DBS was detected; BTD molecular analysis showed the proband to be compound heterozygous for the c.1270G>C (p.Asp424His) mild known variant, and for the rare variant c.690C>G (p.Phe230Leu) previously identified by our group. In this study, we provide the biochemical and clinical characterization of a patient carrying the c.690C>G (p.Phe230Leu) variant, and our findings support a possible contribution of this variant to the partial BD phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.